Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06210854
Other study ID # CRMS-83553
Secondary ID IRB00408026
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 2024
Est. completion date July 2026

Study information

Verified date April 2024
Source Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact Kimberly Levinson, MD
Phone 410-955-8240
Email klevins1@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized phase II study. The primary goal of this study is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent human papillomavirus 16 (HPV16) and/or human papillomavirus (HPV18+).


Description:

This is a randomized phase II study. The primary goal of this study is two-fold; one is to determine the safety and tolerability of three monthly pBI-11 DNA administrations in each thigh of patients with persistent HPV16 and/or HPV18+ < cervical intraepithelial neoplasia 2 (CIN2), wherein either 0.1 mL (0.3 mg) of the plasmid DNA is administered intradermally (I.D.) into each thigh (for a total of 0.6 mg DNA at each visit) using a Pharmajet Tropis device, or 0.5 mL (1.5 mg) of the plasmid DNA is administered intramuscularly (I.M.) into each thigh (for a total of 3 mg DNA at each visit) using a Pharmajet Stratis device; and the other is to evaluate the effect of vaccine on (HPV16/18) viral DNA clearance. Secondary goals are to seek preliminary evidence of prevention of disease progression and assess induction of an HPV16/18-specific immune response to select the appropriate regimen for a subsequent phase III clinical trial. Persistence is defined as positivity on two sequential tests. A total of 72 participants will be enrolled in 4 arms of the study in a 2:1:2:1 ratio (24 patients randomized to the intervention and 12 patient randomized to placebo via Tropis device, and 24 patients randomized to the intervention and 12 patient randomized to placebo via Stratis device).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 72
Est. completion date July 2026
Est. primary completion date January 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients must have: Negative for Intraepithelial Lesions (NEIL), Atypical Squamous Cells of Undetermined Significance (ASC-US), or Low-grade Squamous Intraepithelial Lesion (LSIL) determined by cervical cytology AND HPV16 and/or 18+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test, or other FDA-approved HPV genotyping test (Co-infections with HPV types other than HPV16/18 are permissible). 2. Age = 18 years 3. Baseline Eastern Cooperative Oncology Group performance status of 0, 1 at the time of treatment administration. 4. Patients must have adequate organ function at the time of enrollment as defined by the following parameters: - White blood cell count = 3,000 - Absolute lymphocyte number = 500 - Absolute neutrophil count = 1,500 - Platelets = 90,000 - Hemoglobulin = 9 - Total bilirubin < 3 X the institutional limit of normal - Aspartate Aminotransferase (AST)/Alanine Aminotransferase(ALT) < 3 X the institutional limit of normal - Creatinine < 2.5 X the institutional limit of normal 5. Women of child-bearing potential must agree to use long acting contraception (e.g. tubal ligation, intrauterine devine or hormonal implant) or two forms of contraception (e.g. barrier method, oral contraceptives) prior to study entry and for 3 months after final vaccination. 6. Ability to understand and the willingness to sign a written informed consent document. 7. Subject is able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Histologic evidence of CIN2, cervical intraepithelial neoplasia 3 (CIN3), adenocarcinoma in situ or malignancy. 2. Patients with a diagnosis of immunosuppression or active systemic use of immunosuppressive medications such as steroids. 3. Patients who are receiving any other investigational agents within 28 days prior to the first dose. 4. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 5. Patients with a history of systemic autoimmune disease such as multiple sclerosis or systemic lupus erythematosus (SLE), but exclusive of a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease. 6. Patients who are pregnant or breast feeding or plan to become pregnant within five months of first study treatment. 7. Patient with active infection of, or receiving treatment for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), or Hepatitis B Virus (HBV). 8. History of prior malignancy with disease free interval <5 years; however, individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pBI-11
HPV16/18 vaccine

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of Vaccination To determine the safety of repeat administration of pBI-11 DNA vaccine in patients with persistent HPV16/18+ 12 months
Primary Feasibility of Vaccination To determine the feasibility of repeat administration of pBI-11 DNA vaccine in patients with persistent HPV16/18+ 12 months
Primary Effect of Vaccination To assess the effect of pBI-11 vaccination on the clearance of HPV16/18 in cytologic specimens at month 6 6 months
Secondary Impact of Vaccination on Progression to HPV 16/18 To assess the impact of vaccination upon progression to HPV16/18 messenger RNA (mRNA)+ CIN2+ by month 12 12 months
Secondary Levels of HPV16/18 To evaluate the levels and phenotype of circulation HPV16/18 E6/E7-specific T cells in peripheral blood pre- and post-vaccination by each regimen Baseline, 6 months, and 12 months
Secondary Changes in Cytopathology To evaluate changes in cytopathology of specimens taken pre- and post-vaccination by each regimen Baseline, 6 months, and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04098744 - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) Phase 2
Completed NCT04083196 - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years Phase 1
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Withdrawn NCT04430907 - HPV Vaccine in Postpartum Women
Recruiting NCT02593968 - Yallaferon in Chinese Population Phase 2
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed NCT02263378 - A New Supplement for the Immune Response to HPV Infection N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04590521 - HPV Vaccine Immunity in High-risk Women Phase 4
Recruiting NCT05829629 - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women Phase 1
Recruiting NCT06052033 - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection N/A
Recruiting NCT05051852 - HPV Viral Load in Predicting the Prognosis of LSIL
Completed NCT04155294 - Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
Active, not recruiting NCT06452004 - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) N/A
Completed NCT06177236 - Clinic or Self-Sampling for Cervical Cancer Screening N/A
Active, not recruiting NCT04794660 - The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa" Phase 3
Recruiting NCT05509413 - DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections N/A
Recruiting NCT06137950 - Interferon Alpha Therapy for Cervical CINI and HPV Infection Phase 1
Recruiting NCT04171505 - Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
Active, not recruiting NCT05524025 - The SPOT-HPV Study